Bioavailability and central side effects of different carbamazepine tablets
Neuvonen, P.J.
International Journal of Clinical Pharmacology Therapy and Toxicology 23(4): 226-232
1985
ISSN/ISBN: 0174-4879 PMID: 3997307 Document Number: 251474
The bioavailabilty and central side effects of 5 carbamazepine tablets 0-96 h) of these tablets. On the tablets with the slowest absorption the serum concentrations were still, 24 h after the ingestion, more than 90% of the Cmax. Central side effects (dizziness, ataxia) were significantly (P < 0.01) more common when a brand of tablets with a rapid absorption was used. These tablets were characterized by a rapid dissolution in vitro in 0.1 N HCl. The total bioavailability of carbamazepine does not decrease despite moderate prolongation of the absorption phase. The pure AUC-data alone are inadequate to characterize the clinical equivalency of carbamazepine products. Formulations with a low absorption may be preferable: central side effects are less common and serum concentrations more constant.